035 AIM2 regulates anti-tumor immunity from dendritic cell vaccination within the melanoma microenvironment
Successful immunotherapy strategies for melanoma must elicit the infiltration of CD8+ T cells into the tumor, which is mediated by the recognition of tumor-derived, cytosolic DNA by the cGAS –STING-type I interferon (IFN) signaling pathway in tumor-infiltrating dendritic cells. However, cytosolic DNA can also be recognized by AIM2, a cytosolic DNA sensor that generates IL-1β and IL-18, and also induces pyroptosis, whose function in the melanoma microenvironment remains unclear. Here we report that an intravenously injected premelanosome protein (PMEL) peptide-pulsed Aim2-deficient dendritic cell vaccine (Aim2−/− DC-PMEL) significantly improves the efficacy of adoptive T-cell therapy (ACT) and anti-PD-1 immunotherapy in WT mice with B16F10 melanoma compared to similar treatm ent with the wild-type (WT) DC-PMEL.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: K. Fukuda, R. Riding, A. Khvorova, K. Fitzgerald, J.E. Harris Tags: Adaptive and Auto-Immunity Source Type: research
More News: Dermatology | Immunotherapy | Insect Bites & Stings | Melanoma | Skin | Skin Cancer | Vaccines